ReviewFrontiers in nutrition2026
Methionine restriction in cancer: a dietary insight for therapy.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications.Experimental hematology & oncology · 2026Review
- The Methionine-Mitochondria Axis in Cancer: Metabolic Cross-Talk and Therapeutic Vulnerabilities.Current pharmacology reports · 2026Review
- Synergy of a Low-methionine Diet and Reduced-dose Cisplatinum Eradicates Experimental Lung-cancer Bone Metastases in a Nude-mouse Model.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methionine, one of the essential amino acids that needs to be obtained through protein-rich diet, provides important sulfur elements for the human body, which is crucial for protein synthesis, antioxidant and metabolic regulation. Many tumors develop a metabolic dependency due to the lack of a working methionine salvage pathway, which can be targeted by methionine restriction (MR). Results: The core mechanism of MR lies in disrupting one-carbon metabolism and epigenetic regulation that rely on methionine, depleting the crucial metabolite S-adenosylmethionine (SAM), thereby inhibiting histone/DNA methylation, disrupting redox homeostasis, and ultimately inducing cell cycle arrest and apoptosis. Substantial evidence indicates that MR, achieved by specific metabolic enzyme inhibitors or diet with special formulations, can intervene in tumor progression from a metabolic standpoint. Additionally, combining methionine restriction with existing treatments can achieve satisfactory outcomes in the clinical management of various tumors. Conclusion: This article provides insights into the research and its translational potential of methionine restriction as a promising strategy for cancer treatment, with the emphasis on the contributions that advance the field and better serve the clinical research community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.